Knight Therapeutics (GUD) Competitors C$6.45 +0.08 (+1.26%) As of 08/22/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesBuy This Stock GUD vs. BHC, THCX, CRON, TLRY, ACB, WEED, OGI, CPH, FIRE, and EPIShould you be buying Knight Therapeutics stock or one of its competitors? The main competitors of Knight Therapeutics include Bausch Health Companies (BHC), Hydropothecary (THCX), Cronos Group (CRON), Tilray Brands (TLRY), Aurora Cannabis (ACB), Canopy Growth (WEED), Organigram (OGI), Cipher Pharmaceuticals (CPH), Supreme Cannabis (FIRE), and ESSA Pharma (EPI). These companies are all part of the "drug manufacturers - specialty & generic" industry. Knight Therapeutics vs. Its Competitors Bausch Health Companies Hydropothecary Cronos Group Tilray Brands Aurora Cannabis Canopy Growth Organigram Cipher Pharmaceuticals Supreme Cannabis ESSA Pharma Knight Therapeutics (TSE:GUD) and Bausch Health Companies (TSE:BHC) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings. Which has more volatility and risk, GUD or BHC? Knight Therapeutics has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Which has higher valuation & earnings, GUD or BHC? Knight Therapeutics has higher earnings, but lower revenue than Bausch Health Companies. Knight Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKnight TherapeuticsC$348.70M1.87-C$30.73M-C$0.30-21.53Bausch Health CompaniesC$6.69B0.40-C$125.65M-C$0.68-15.19 Do insiders and institutionals have more ownership in GUD or BHC? 12.6% of Knight Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Bausch Health Companies shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by company insiders. Comparatively, 11.3% of Bausch Health Companies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor GUD or BHC? In the previous week, Bausch Health Companies had 12 more articles in the media than Knight Therapeutics. MarketBeat recorded 12 mentions for Bausch Health Companies and 0 mentions for Knight Therapeutics. Knight Therapeutics' average media sentiment score of 0.20 beat Bausch Health Companies' score of -0.18 indicating that Knight Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Knight Therapeutics Neutral Bausch Health Companies Neutral Do analysts recommend GUD or BHC? Knight Therapeutics presently has a consensus target price of C$7.15, suggesting a potential upside of 10.85%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Knight Therapeutics is more favorable than Bausch Health Companies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Knight Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Bausch Health Companies 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is GUD or BHC more profitable? Bausch Health Companies has a net margin of -1.88% compared to Knight Therapeutics' net margin of -8.81%. Bausch Health Companies' return on equity of 15.87% beat Knight Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Knight Therapeutics-8.81% -4.04% 0.51% Bausch Health Companies -1.88%15.87%4.16% SummaryKnight Therapeutics beats Bausch Health Companies on 9 of the 17 factors compared between the two stocks. Get Knight Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GUD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GUD vs. The Competition Export to ExcelMetricKnight TherapeuticsDrug Manufacturers IndustryMedical SectorTSE ExchangeMarket CapC$652.42MC$2.26BC$5.76BC$6.37BDividend YieldN/A2.92%4.41%6.72%P/E Ratio-21.534.2931.1073.11Price / Sales1.87691.66436.341,702.25Price / Cash3.8510.3737.7383.29Price / Book0.8411.959.534.90Net Income-C$30.73MC$20.70BC$3.26BC$301.20M7 Day Performance3.70%1.17%2.10%1.35%1 Month Performance5.39%4.45%2.81%1.88%1 Year PerformanceN/A3.65%30.56%27.39% Knight Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GUDKnight Therapeutics1.431 of 5 starsC$6.45+1.3%C$7.15+10.9%+13.0%C$652.42MC$348.70M-21.53725BHCBausch Health CompaniesN/AC$9.63+4.6%N/A+32.6%C$2.50BC$6.69B-14.0919,900Trending NewsAnalyst RevisionHigh Trading VolumeTHCXHydropothecaryN/AC$5.30+6.6%N/A+0.0%C$949.11MN/A0.00N/AHigh Trading VolumeCRONCronos GroupN/AC$3.53-3.3%N/A+15.3%C$932.15MC$76.86M-19.64450High Trading VolumeTLRYTilray BrandsN/AC$1.32+3.9%N/A-37.6%C$850.57MC$610.34M-3.192,650High Trading VolumeACBAurora Cannabis0.5927 of 5 starsC$7.25+1.0%C$8.75+20.7%-17.3%C$396.63MC$195.83M-8.951,073High Trading VolumeWEEDCanopy Growth0.2163 of 5 starsC$2.14-1.8%C$1.55-27.6%-78.8%C$344.26MC$519.68M-0.312,700High Trading VolumeOGIOrganigram2.7653 of 5 starsC$2.22-1.3%C$3.33+49.8%-17.0%C$274.26MC$180.58M-4.69987High Trading VolumeCPHCipher Pharmaceuticals0.6688 of 5 starsC$14.94-0.7%C$14.75-1.3%-6.8%C$268.22MC$19.03M16.505FIRESupreme CannabisN/AN/AN/AN/AC$259.40MC$53.29M-10.97400News CoverageEPIESSA PharmaN/AC$8.20+7.2%N/A+0.0%C$237.87MN/A-8.2725 Related Companies and Tools Related Companies BHC Alternatives THCX Alternatives CRON Alternatives TLRY Alternatives ACB Alternatives WEED Alternatives OGI Alternatives CPH Alternatives FIRE Alternatives EPI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:GUD) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access